PMID- 23503938
OWN - NLM
STAT- MEDLINE
DCOM- 20140613
LR  - 20211021
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 33
IP  - 9
DP  - 2013 Sep
TI  - The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity 
      C-reactive protein for predicting rheumatoid arthritis in anti-cyclic 
      citrullinated peptide antibody-negative patients with recent-onset 
      undifferentiated arthritis.
PG  - 2309-14
LID - 10.1007/s00296-013-2716-1 [doi]
AB  - Anti-cyclic citrullinated peptide (anti-CCP) antibodies are well-established 
      serological markers that show high sensitivity and specificity in early 
      rheumatoid arthritis (RA) and are associated with bone erosions of RA. However, 
      some patients subsequently progress to RA even if there is no presence of 
      anti-CCP antibodies in an early stage. The aim of this study is to evaluate the 
      diagnostic utility of matrix metalloproteinase-3 (MMP-3), high-sensitivity 
      C-reactive protein (hsCRP) and IgM rheumatoid factor for predicting RA in 
      anti-CCP-negative patients with recent-onset undifferentiated arthritis (UA). 
      Baseline levels of those markers were measured at the entry of the study. A total 
      of 99 patients with UA were included, among them 44 patients (44.4 %) had been 
      classified as having RA by a skilled rheumatologist at some point during 1-year 
      follow-up. Of these 99 patients, 34 patients (34.3 %) had anti-CCP antibodies and 
      65 patients (65.7 %) had no anti-CCP antibodies. Eleven patients who were 
      anti-CCP-negative developed RA. We compared sensitivity, specificity, positive 
      predictive value and negative predictive value of serum markers of these 
      anti-CCP-negative RA patients. The combined usage of MMP-3 with hsCRP is 
      relatively superior to other markers as predictors of RA.
FAU - Hiura, Kazuya
AU  - Hiura K
AD  - Division of Life Science, Hokkaido Pharmaceutical University School of Pharmacy, 
      7-1 Katsuraoka-cho, Otaru, Hokkaido 047-0264, Japan.
FAU - Iwaki-Egawa, Sachiko
AU  - Iwaki-Egawa S
FAU - Kawashima, Toshiyuki
AU  - Kawashima T
FAU - Fujisawa, Shin-Ichi
AU  - Fujisawa S
FAU - Takeda, Tsuyoshi
AU  - Takeda T
FAU - Komori, Hitoshi
AU  - Komori H
FAU - Watanabe, Yasuhiro
AU  - Watanabe Y
LA  - eng
PT  - Journal Article
DEP - 20130317
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Autoantibodies)
RN  - 0 (Peptides, Cyclic)
RN  - 0 (cyclic citrullinated peptide)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthritis, Rheumatoid/blood/*diagnosis/immunology
MH  - Autoantibodies/*blood
MH  - C-Reactive Protein/*analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Peptides, Cyclic/*immunology
EDAT- 2013/03/19 06:00
MHDA- 2014/06/15 06:00
CRDT- 2013/03/19 06:00
PHST- 2012/07/20 00:00 [received]
PHST- 2013/03/04 00:00 [accepted]
PHST- 2013/03/19 06:00 [entrez]
PHST- 2013/03/19 06:00 [pubmed]
PHST- 2014/06/15 06:00 [medline]
AID - 10.1007/s00296-013-2716-1 [doi]
PST - ppublish
SO  - Rheumatol Int. 2013 Sep;33(9):2309-14. doi: 10.1007/s00296-013-2716-1. Epub 2013 
      Mar 17.